Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07459543CT.gov A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India | — | Not Yet Recruiting | — | — | — |
NCT06319196CT.gov Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | — | Recruiting | — | — | — |
NCT07518043CT.gov A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07476326CT.gov Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | — | Not Yet Recruiting | — | — | — |
NCT06365619CT.gov Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | — | Recruiting | — | — | — |
NCT07504796CT.gov ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | — | Recruiting | — | — | — |
NCT07223411CT.gov Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | — | Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT05717140CT.gov Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | — | Withdrawn | — | — | — |
NCT06624644CT.gov A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | — | Recruiting | — | — | — |
Show 179 more trialsShow fewer
NCT06712927CT.gov Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | — | Recruiting | — | — | — |
NCT07092670CT.gov MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. | — | Recruiting | — | — | — |
NCT06794775CT.gov SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma | — | Recruiting | — | — | — |
NCT07091695CT.gov Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | — | Completed | — | — | — |
NCT06683755CT.gov Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | — | Not Yet Recruiting | — | — | — |
NCT06587451CT.gov Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® | — | Terminated | — | — | — |
NCT06488482CT.gov Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma | — | Recruiting | — | — | — |
NCT07079644CT.gov Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | — | Completed | — | — | — |
NCT05629546CT.gov Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | — | Recruiting | — | — | — |
NCT06246916CT.gov A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | — | Recruiting | — | — | — |
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT05896839CT.gov Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | — | Recruiting | — | — | — |
NCT06264180CT.gov VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | — | Recruiting | — | — | — |
NCT06112314CT.gov IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | — | Recruiting | — | — | — |
NCT06295159CT.gov Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | — | Recruiting | — | — | — |
NCT07436390CT.gov IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | — | Completed | — | — | — |
NCT06640530CT.gov Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | — | Active Not Recruiting | — | — | — |
NCT06240143CT.gov Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | — | Recruiting | — | — | — |
NCT06250335CT.gov Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT06101134CT.gov A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | — | Active Not Recruiting | — | — | — |
NCT06054555CT.gov A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT06034860CT.gov Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | — | Terminated | — | — | — |
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06163170CT.gov A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | — | Completed | — | — | — |
NCT05418972CT.gov A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma | — | Active Not Recruiting | — | — | — |
NCT05907122CT.gov A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma | — | Completed | — | — | — |
NCT05926960CT.gov A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT05912244CT.gov A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | — | Active Not Recruiting | — | — | — |
NCT05655312CT.gov MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | — | Recruiting | — | — | — |
NCT05496192CT.gov A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | — | Withdrawn | — | — | — |
NCT06112808CT.gov A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | — | Active Not Recruiting | — | — | — |
NCT05625399CT.gov A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | — | Active Not Recruiting | — | — | — |
NCT05428007CT.gov Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | — | Recruiting | — | — | — |
NCT05498792CT.gov Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | — | Recruiting | — | — | — |
NCT05598853CT.gov Intrathecal Double Checkpoint Inhibition | — | Active Not Recruiting | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05180799CT.gov A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05297565CT.gov A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection | — | Completed | — | — | — |
NCT05423262CT.gov A Study of TRK-950 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05089370CT.gov Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | — | Active Not Recruiting | — | — | — |
NCT04913025CT.gov REduced Frequency ImmuNE Checkpoint Inhibition in Cancers | — | Unknown | — | — | — |
NCT05354102CT.gov A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | — | Unknown | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05289193CT.gov CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | — | Active Not Recruiting | — | — | — |
NCT05302921CT.gov Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | — | Completed | — | — | — |
NCT05116202CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | — | Completed | — | — | — |
NCT04988841CT.gov Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma | — | Completed | — | — | — |
NCT04930783CT.gov NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT05061017CT.gov Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | — | Completed | — | — | — |
NCT04572451CT.gov Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | — | Recruiting | — | — | — |
NCT04901988CT.gov Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION | — | Terminated | — | — | — |
NCT05002569CT.gov A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT04688658CT.gov Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | — | Terminated | — | — | — |
NCT05714371CT.gov Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | — | Completed | — | — | — |
NCT04940299CT.gov Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04967196CT.gov Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | — | Terminated | — | — | — |
NCT04949113CT.gov Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | — | Active Not Recruiting | — | — | — |
NCT04899921CT.gov Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | — | Terminated | — | — | — |
NCT04655157CT.gov Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | — | Terminated | — | — | — |
NCT04741997CT.gov Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | — | Recruiting | — | — | — |
NCT04835805CT.gov A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | — | Active Not Recruiting | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04495010CT.gov Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants | — | Withdrawn | — | — | — |
NCT04731467CT.gov A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | — | Completed | — | — | — |
NCT04698187CT.gov CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | — | Terminated | — | — | — |
NCT04695977CT.gov CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | — | Terminated | — | — | — |
NCT04462406CT.gov Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | — | Active Not Recruiting | — | — | — |
NCT04526730CT.gov Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | — | Completed | — | — | — |
NCT04493203CT.gov Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | — | Completed | — | — | — |
NCT04581382CT.gov Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | — | Completed | — | — | — |
NCT04464759CT.gov A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT04562129CT.gov IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | — | Recruiting | — | — | — |
NCT04495257CT.gov A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | — | Completed | — | — | — |
NCT04114136CT.gov Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT04330430CT.gov Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease | — | Completed | — | — | — |
NCT04401995CT.gov Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab | — | Completed | — | — | — |
NCT04223648CT.gov Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT04410445CT.gov Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | — | Terminated | — | — | — |
NCT04107168CT.gov Microbiome Immunotherapy Toxicity and Response Evaluation | — | Unknown | — | — | — |
NCT04074967CT.gov Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | — | Active Not Recruiting | — | — | — |
NCT04187833CT.gov Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes | — | Completed | — | — | — |
NCT04125719CT.gov PVSRIPO in Combination With Nivolumab in Melanoma | — | Withdrawn | — | — | — |
NCT04382664CT.gov UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | — | Completed | — | — | — |
NCT04427306CT.gov Neoadjuvant T-VEC in High Risk Early Melanoma | — | Suspended | — | — | — |
NCT04091750CT.gov Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT04250246CT.gov A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | — | Unknown | — | — | — |
NCT03958383CT.gov IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | — | Terminated | — | — | — |
NCT04208958CT.gov Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer | — | Completed | — | — | — |
NCT04133948CT.gov Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma | — | Completed | — | — | — |
NCT04013854CT.gov Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | — | Active Not Recruiting | — | — | — |
NCT03816332CT.gov Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | — | Active Not Recruiting | — | — | — |
NCT04007588CT.gov A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | — | Withdrawn | — | — | — |
NCT04044859CT.gov ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | — | Active Not Recruiting | — | — | — |
NCT03340129CT.gov Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | — | Recruiting | — | — | — |
NCT04017897CT.gov The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma | — | Unknown | — | — | — |
NCT03999749CT.gov A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT03719131CT.gov Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | — | Active Not Recruiting | — | — | — |
NCT03991130CT.gov High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT03834623CT.gov Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03743766CT.gov Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03724968CT.gov Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | — | Terminated | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03235245CT.gov Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | — | Active Not Recruiting | — | — | — |
NCT03354962CT.gov Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | — | Terminated | — | — | — |
NCT03711188CT.gov A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma | — | Completed | — | — | — |
NCT03635983CT.gov A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | — | Completed | — | — | — |
NCT03620019CT.gov Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | — | Completed | — | — | — |
NCT03618641CT.gov CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | — | Completed | — | — | — |
NCT03528408CT.gov Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | — | Unknown | — | — | — |
NCT03502330CT.gov APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | — | Completed | — | — | — |
NCT03563729CT.gov Melanoma Metastasized to the Brain and Steroids | — | Recruiting | — | — | — |
NCT03565406CT.gov A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | — | Terminated | — | — | — |
NCT03470922CT.gov A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT03435640CT.gov REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | — | Terminated | — | — | — |
NCT03511391CT.gov CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | — | Completed | — | — | — |
NCT03126461CT.gov SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | — | Withdrawn | — | — | — |
NCT03400332CT.gov A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | — | Completed | — | — | — |
NCT03374839CT.gov Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients | — | Unknown | — | — | — |
NCT03259425CT.gov Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | — | Terminated | — | — | — |
NCT03301636CT.gov A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | — | Terminated | — | — | — |
NCT03161756CT.gov Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | — | Unknown | — | — | — |
NCT03167177CT.gov QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | — | Withdrawn | — | — | — |
NCT03329846CT.gov An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT03220009CT.gov Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | — | Withdrawn | — | — | — |
NCT03033576CT.gov Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | — | Completed | — | — | — |
NCT03293784CT.gov TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma | — | Completed | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03190174CT.gov Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | — | Completed | — | — | — |
NCT03123783CT.gov CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | — | Completed | — | — | — |
NCT03166397CT.gov Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients | — | Unknown | — | — | — |
NCT03068455CT.gov An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma | — | Completed | — | — | — |
NCT03165409CT.gov Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | — | Completed | — | — | — |
NCT02983045CT.gov A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | — | Completed | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02857569CT.gov A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02970981CT.gov Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | — | Completed | — | — | — |
NCT02437279CT.gov Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients | — | Unknown | — | — | — |
NCT02977052CT.gov Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | — | Unknown | — | — | — |
NCT02905266CT.gov A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | — | Completed | — | — | — |
NCT02659540CT.gov Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | — | Completed | — | — | — |
NCT02897765CT.gov A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | — | Completed | — | — | — |
NCT02983006CT.gov Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | — | Completed | — | — | — |
NCT02736123CT.gov Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | — | Withdrawn | — | — | — |
NCT02935790CT.gov Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | — | Completed | — | — | — |
NCT02718066CT.gov Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02771626CT.gov Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT02656706CT.gov Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02723006CT.gov Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | — | Terminated | — | — | — |
NCT02731729CT.gov Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy | — | Completed | — | — | — |
NCT02658890CT.gov An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02714218CT.gov A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT05063058CT.gov Biomarker-driven Therapy for Melanoma | — | Completed | — | — | — |
NCT02599402CT.gov Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT02637531CT.gov A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | — | Unknown | — | — | — |
NCT02553642CT.gov Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | — | Completed | — | — | — |
NCT02224781CT.gov Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | — | Active Not Recruiting | — | — | — |
NCT02523313CT.gov Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | — | Completed | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02304458CT.gov Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | — | Completed | — | — | — |
NCT02388906CT.gov Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma | — | Completed | — | — | — |
NCT02320058CT.gov An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself | — | Completed | — | — | — |
NCT02423863CT.gov In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® | — | Completed | — | — | — |
NCT02327078CT.gov A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | — | Completed | — | — | — |
NCT02374242CT.gov Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT02302339CT.gov A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT02259231CT.gov RTA 408 Capsules in Patients With Melanoma - REVEAL | — | Completed | — | — | — |
NCT02073123CT.gov Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01927419CT.gov Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | — | Completed | — | — | — |
NCT01721772CT.gov Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | — | Completed | — | — | — |
NCT01621490CT.gov PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | — | Completed | — | — | — |
NCT01024231CT.gov Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | — | Completed | — | — | — |
NCT00441337CT.gov A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies | — | Completed | — | — | — |
NCT02186249CT.gov Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma | — | No Longer Available | — | — | — |
NCT06590480CT.gov An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Bristol-Myers Squibb | Approved | BB · 69 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →